Vascular endothelial growth factor inhibitors for retinopathy of prematurity

<p> <b>O.V. Zhukova<sup>1</sup>, I.A.&nbsp;Mal’tseva<sup>2</sup>, A.V. Zolotarev<sup>1,2</sup></b> </p> <p> <b><sup>1</sup>Samara State Medical University, Samara, Russian Federation</b> </p> <p&...

Full description

Saved in:
Bibliographic Details
Main Authors: O.V. Zhukova, I.A. Mal’tseva, A.V. Zolotarev
Format: Article
Language:Russian
Published: Prime-Media 2020-11-01
Series:РМЖ "Клиническая офтальмология"
Online Access:http://clinopht.com/upload/iblock/382/382d4cb3678da802d03a80b029fd535d.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841526830720352256
author O.V. Zhukova
I.A. Mal’tseva
A.V. Zolotarev
author_facet O.V. Zhukova
I.A. Mal’tseva
A.V. Zolotarev
author_sort O.V. Zhukova
collection DOAJ
description <p> <b>O.V. Zhukova<sup>1</sup>, I.A.&nbsp;Mal’tseva<sup>2</sup>, A.V. Zolotarev<sup>1,2</sup></b> </p> <p> <b><sup>1</sup>Samara State Medical University, Samara, Russian Federation</b> </p> <p> <b><sup>2</sup>T.I. Eroshevskiy Samara Regional Clinical Ophthalmological Hospital, Samara, Russian Federation</b> </p> <p> <i>The article addresses current treatment modalities for threshold retinopathy of prematurity (ROP) and aggressive posterior retinopathy of prematurity (APROP), in particular, intravitreal administration of vascular endothelial growth factor (VEGF) inhibitors. The results of multicenter clinical trials evaluating pegaptanib, bevacizumab, and ranibizumab are discussed. The clinical effect of intravitreal anti-VEGF drugs was compared to the efficacy of laser retinal photocoagulation. In children with ROP, anti-VEGF drugs are equal or even superior to the conventional laser retinal photocoagulation in terms of clinical efficacy. No negative effects of anti-VEGF drugs on ocular tissues or vasculature development in premature children were demonstrated. Moreover, several studies show the potential efficacy of intravitreal anti-VEGF drugs plus avascular zone photocoagulation for APROP. Finally, our experience with intravitreal ranibizumab for threshold ROP and plus d isease in a patient who was followed-up for subsequent 9 years is described.</i> </p> <p> <i><b>Keywords</b>: retinopathy of prematurity, plus disease, aggressive posterior retinopathy of prematurity, anti-VEGF drugs, ranibizumab.</i> </p> <p> <i><b>For citation: </b>Zhukova O.V., Mal’tseva I.A., Zolotarev A.V. Vascular endothelial growth factor inhibitors for retinopathy of prematurity. Russian Journal of Clinical Ophthalmology. 2020;20(4):216–220. DOI: 10.32364/2311-7729-2020-20-4-216-220.</i> </p> <i><br> </i><br>
format Article
id doaj-art-ce4dbf9650a8469faff269a06af3e794
institution Kabale University
issn 2311-7729
2619-1571
language Russian
publishDate 2020-11-01
publisher Prime-Media
record_format Article
series РМЖ "Клиническая офтальмология"
spelling doaj-art-ce4dbf9650a8469faff269a06af3e7942025-01-16T09:39:39ZrusPrime-MediaРМЖ "Клиническая офтальмология"2311-77292619-15712020-11-0120431225Vascular endothelial growth factor inhibitors for retinopathy of prematurityO.V. Zhukova0I.A. Mal’tseva1A.V. Zolotarev2Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399<p> <b>O.V. Zhukova<sup>1</sup>, I.A.&nbsp;Mal’tseva<sup>2</sup>, A.V. Zolotarev<sup>1,2</sup></b> </p> <p> <b><sup>1</sup>Samara State Medical University, Samara, Russian Federation</b> </p> <p> <b><sup>2</sup>T.I. Eroshevskiy Samara Regional Clinical Ophthalmological Hospital, Samara, Russian Federation</b> </p> <p> <i>The article addresses current treatment modalities for threshold retinopathy of prematurity (ROP) and aggressive posterior retinopathy of prematurity (APROP), in particular, intravitreal administration of vascular endothelial growth factor (VEGF) inhibitors. The results of multicenter clinical trials evaluating pegaptanib, bevacizumab, and ranibizumab are discussed. The clinical effect of intravitreal anti-VEGF drugs was compared to the efficacy of laser retinal photocoagulation. In children with ROP, anti-VEGF drugs are equal or even superior to the conventional laser retinal photocoagulation in terms of clinical efficacy. No negative effects of anti-VEGF drugs on ocular tissues or vasculature development in premature children were demonstrated. Moreover, several studies show the potential efficacy of intravitreal anti-VEGF drugs plus avascular zone photocoagulation for APROP. Finally, our experience with intravitreal ranibizumab for threshold ROP and plus d isease in a patient who was followed-up for subsequent 9 years is described.</i> </p> <p> <i><b>Keywords</b>: retinopathy of prematurity, plus disease, aggressive posterior retinopathy of prematurity, anti-VEGF drugs, ranibizumab.</i> </p> <p> <i><b>For citation: </b>Zhukova O.V., Mal’tseva I.A., Zolotarev A.V. Vascular endothelial growth factor inhibitors for retinopathy of prematurity. Russian Journal of Clinical Ophthalmology. 2020;20(4):216–220. DOI: 10.32364/2311-7729-2020-20-4-216-220.</i> </p> <i><br> </i><br>http://clinopht.com/upload/iblock/382/382d4cb3678da802d03a80b029fd535d.pdf
spellingShingle O.V. Zhukova
I.A. Mal’tseva
A.V. Zolotarev
Vascular endothelial growth factor inhibitors for retinopathy of prematurity
РМЖ "Клиническая офтальмология"
title Vascular endothelial growth factor inhibitors for retinopathy of prematurity
title_full Vascular endothelial growth factor inhibitors for retinopathy of prematurity
title_fullStr Vascular endothelial growth factor inhibitors for retinopathy of prematurity
title_full_unstemmed Vascular endothelial growth factor inhibitors for retinopathy of prematurity
title_short Vascular endothelial growth factor inhibitors for retinopathy of prematurity
title_sort vascular endothelial growth factor inhibitors for retinopathy of prematurity
url http://clinopht.com/upload/iblock/382/382d4cb3678da802d03a80b029fd535d.pdf
work_keys_str_mv AT ovzhukova vascularendothelialgrowthfactorinhibitorsforretinopathyofprematurity
AT iamaltseva vascularendothelialgrowthfactorinhibitorsforretinopathyofprematurity
AT avzolotarev vascularendothelialgrowthfactorinhibitorsforretinopathyofprematurity